Enlivex Ltd.

What they do

Enlivex operates a dual strategy: clinical development of Allocetra, an off-the-shelf cell therapy that reprograms macrophages to treat inflammatory conditions (currently focused on osteoarthritis), and a treasury operation holding the RAIN token as its primary reserve asset. The company is incorporated in Israel and listed on Nasdaq.

Revenue drivers

• Allocetra (clinical-stage) — No commercial revenue; potential future sales depend on regulatory approval for osteoarthritis and other inflammatory indications.
• RAIN token treasury — Primary treasury reserve asset; no revenue generated, but gains/losses on the token's value contribute to reported net income.

Recent performance

For fiscal year 2025, Enlivex reported net income of $1.24 billion, a dramatic swing from a net loss of $15.0 million in 2024, driven by gains from its RAIN token holdings. Diluted EPS was $25.48 in 2025 versus a loss per share of $0.73 in 2024. Operating cash flow remained negative at -$10.4 million in 2025, though it improved from -$13.0 million in 2024. As of December 31, 2025, total assets were $2.33 billion, liabilities $392.1 million, and shareholders' equity $1.93 billion, with cash and equivalents of only $1.9 million.

Strategy

Enlivex has adopted a treasury policy centered on the RAIN token, aiming to provide investors exposure to prediction markets and position RAIN as 'digital capital.' On the clinical side, the company continues to develop Allocetra as a universal, off-the-shelf cell therapy, with osteoarthritis as the primary indication. The company describes itself as a 'quality longevity company,' intending to combine clinical advancements with its treasury model.

Risks

• Clinical-stage product — Allocetra has no approved products or commercial revenue; failure in trials or regulatory denial would impair the business.
• Treasury asset volatility — The RAIN token's value is highly volatile, as evidenced by the $1.24 billion net income swing in 2025, which could reverse and lead to large writedowns.
• Low cash reserves — Despite large reported assets, cash and equivalents were only $1.9 million at year-end 2025, which may not sustain operations without further sale of RAIN tokens or financing.
• Regulatory and competitive — The immunotherapy space is competitive, and Allocetra faces uncertainties in clinical development, manufacturing, and market acceptance.

Outlook

Management expects to continue its dual strategy, advancing Allocetra's clinical program while maintaining RAIN as its primary treasury reserve. The company plans to use the substantial asset base to fund operations and potentially pursue further clinical development. However, the negative operating cash flow and minimal cash position suggest near-term dependence on token sales or capital raises.